

# ЕКСПЕРИМЕНТАЛЬНА ТА КЛІНІЧНА ФАРМАКОЛОГІЯ

Recommended by Doctor of Medicine, Professor N. I. Filimonova

UDC 547.752:615.281.9:579.8

<https://doi.org/10.24959/nphj.18.2202>

Ye. I. Syumka, T. P. Osolodchenko\*, V. P. Chernykh, L. A. Shemchuk

National University of Pharmacy

\* State Institution “Institute of Microbiology and Immunology named after I. I. Mechnikov of the National Academy of Medical Sciences of Ukraine”

## The study of the antimicrobial activity of ethylene-N,N'-bis(spiroindole-3,3'-pyrrolo[3,4-c]pyrrole-2a',5a'-dihydro-2,2',6'(1H,1'H,5'H)-trione) derivatives

**Aim.** To find compounds with the antimicrobial activity in the series of N,N'-bis(spiroindole-3,3'-pyrrolo[3,4-c]pyrrol-2a',5a'-dihydro-2,2',6'(1H,1'H,5'H)-trione) derivatives.

**Materials and methods.** The antimicrobial activity was studied by the agar diffusion method.

**Results and discussion.** The antimicrobial screening data revealed the pronounced biological activity of ethylene-N,N'-bis(spiroindole-3,3'-pyrrolo[3,4-c]pyrrol-2a',5a'-dihydro-2,2',6'(1H,1'H,5'H)-trione) derivatives against gramnegative (*Proteus vulgaris*, *Escherichia coli*, *Pseudomonas aeruginosa*) and grampositive (*Staphylococcus aureus*, *Bacillus subtilis*) bacteria and as well as against *Candida albicans* fungi.

**Conclusions.** The antibacterial activity of ethylene-N,N'-bis(spiroindole-3,3'-pyrrolo[3,4-c]pyrrol-2a',5a'-dihydro-2,2',6'(1H,1'H,5'H)-trione) derivatives has been studied. The compounds with a significant level of the antimicrobial activity against gramnegative bacteria (*Proteus vulgaris*, *Escherichia coli*, *Pseudomonas aeruginosa*), grampositive bacteria (*Staphylococcus aureus*, *Bacillus subtilis*), as well as against fungi (*Candida albicans*) have been found. According to the data of the microbiological screening the most active compounds appeared to be ethylene-N,N'-bis(spiroindole-3,3'-pyrrolo[3,4-c]pyrrol-2a',5a'-dihydro-2,2',6'(1H,1'H,5'H)-trione) **1** and ethylene-N,N'-bis(spiroindole-3,3'-pyrrolo[3,4-c]pyrrol-5'-methyl-2a',5a'-dihydro-2,2',6'(1H,1'H,5'H)-trione) **2**.

**Key words:** bis-spiro-2-oxindole; double drugs; bacteria; antibacterial agents

Є. І. Сюмека, Т. П. Осолодченко, В. П. Черних, Л. А. Шемчук

### Дослідження антимікробної активності похідних етилен-N,N'-біс(спіроіндол-3,3'-піроло[3,4-с]пірол-2а',5а'-дигідро-2,2',6'(1H,1'H,5'H)-триону)

**Мета роботи** – виявлення сполук з антимікробною активністю в ряду похідних етилен-N,N'-біс(спіроіндол-3,3'-піроло[3,4-с]пірол-2а',5а'-дигідро-2,2',6'(1H,1'H,5'H)-триону).

**Матеріали та методи.** Дослідження антимікробної активності методом дифузії в агар у модифікації колодязів.

**Результати та їх обговорення.** Дані мікробіологічного скринінгу показали виражену біологічну дію похідних етилен-N,N'-біс(спіроіндол-3,3'-піроло[3,4-с]пірол-2а',5а'-дигідро-2,2',6'(1H,1'H,5'H)-триону) відносно грамнегативних *Proteus vulgaris*, *Escherichia coli*, *Pseudomonas aeruginosa* і грампозитивних бактерій *Staphylococcus aureus*, *Bacillus subtilis* та грибів *Candida albicans*.

**Висновки.** Досліджено антибактеріальну активність похідних етилен-N,N'-біс(спіроіндол-3,3'-піроло[3,4-с]пірол-2а',5а'-дигідро-2,2',6'(1H,1'H,5'H)-триону). Виявлені сполуки зі значним рівнем біологічної активності відносно грамнегативних бактерій: *Proteus vulgaris*, *Escherichia coli*, *Pseudomonas aeruginosa*, грампозитивних бактерій: *Staphylococcus aureus*, *Bacillus subtilis* та грибів *Candida albicans*. За даними мікробіологічного скринінгу найбільш активними виявились сполуки: етилен-N,N'-біс(спіроіндол-3,3'-піроло[3,4-с]пірол-2а',5а'-дигідро-2,2',6'(1H,1'H,5'H)-трион) **1** та етилен-N,N'-біс(спіроіндол-3,3'-піроло[3,4-с]пірол-5'-метил-2а',5а'-дигідро-2,2',6'(1H,1'H,5'H)-трион) **2**.

**Ключові слова:** біс-спіро-2-оксіндол; подвійні ліки; бактерії; антибактеріальні засоби

Е. И. Сюмека, Т. П. Осолодченко, В. П. Черных, Л. А. Шемчук

### Исследование антимикробной активности производных этилен-N,N'-бис(спироиндол-3,3'-пирроло[3,4-с]пиррол-2а',5а'-дигидро-2,2',6'(1H,1'H,5'H)-триона)

**Цель работы** – обнаружение соединений с антимикробной активностью в ряду производных этилен-N,N'-бис(спироиндол-3,3'-пирроло[3,4-с]пиррол-2а',5а'-дигидро-2,2',6'(1H,1'H,5'H)-триона).

**Материалы и методы.** Исследование антимикробной активности методом диффузии в агар в модификации колодцев.

**Результаты и их обсуждение.** Данные микробиологического скрининга показали выраженное биологическое действие синтезированных соединений относительно грамотрицательных *Proteus vulgaris*, *Escherichia coli*, *Pseudomonas aeruginosa*, грамположительных бактерий *Staphylococcus aureus*, *Bacillus subtilis* и грибов *Candida albicans*.

**Выводы.** Исследована антибактериальная активность производных этилен-N,N'-бис(спироиндол-3,3'-пирроло[3,4-с]пиррол-2а',5а'-дигидро-2,2',6'(1H, 1'H,5'H)-триона). Обнаружены соединения со значительным уровнем биологической активности относительно грамотрицательных бактерий: *Proteus vulgaris*, *Escherichia coli*, *Pseudomonas aeruginosa*, грамположительных бактерий: *Staphylococcus aureus*, *Bacillus subtilis* и грибов *Candida albicans*. По данным микробиологического скрининга наиболее активными оказались соединения: этилен-N,N'-бис(спироиндол-3,3'-пирроло[3,4-с]пиррол-2а',5а'-дигидро-2,2',6'(1H,1'H,5'H)-трион) **1** и этилен-N,N'-бис(спироиндол-3,3'-пирроло[3,4-с]пиррол-5'-метил-2а',5а'-дигидро-2,2',6'(1H,1'H,5'H)-трион) **2**.

**Ключевые слова:** бис-спиро-2-оксиндол; двойные лекарства; бактерии; антибактериальные средства

According to the data published by the WHO, infectious diseases are the 4th ranked cause of mortality in the world. More than 17 million people die of an infectious pathology per year [1]. Difficulties of treatment and prevention of these diseases are caused by a variety of biological forms of causative agents, permanent arising of resistant forms of strains and by emergence of new kinds of dangerous pathogens. Therefore, creation of new antimicrobial drugs is topical issue of medicinal chemistry.

Recently, in synthetic chemistry much attention is paid to spirocombined pyrrolooxindoles, which core is the basis of natural alkaloids that exhibit a pronounced antibacterial activity [2]. The spatial arrangement of the pyrrolooxindole core is the probable reason for its strong binding with tridimensional sites of biotargets in a microbial cell [3]. Since most of the known inhibitors of microbial enzymes have a plane or almost plane structure, they can not bind with specific fragments into biotargets above and below of the molecule plane. This is the cause of their low selectivity [4].

On the other hand, such chemical classes as bis-spirooxindoles, dispirooxindoles and bis-spiroindoles are of great interest for creation of double drugs. It has been proven that development of biologically active compounds comprising two similar pharmacophors bound by the covalent bond leads to a significant increase of the biological activity [5]. Thus, the bis-spirooxindole core is the basis of such alkaloids as *geleganidine C*, *geleganimine B*, *bi-pleiophylline* possessing the antibacterial activity (Fig. 1) [6-9].

Thus, the search of new antimicrobial agents among derivatives of bis-spiro-2-oxindole-3,3'-pyrrole is the promising way to create new effective drugs.

Earlier it was found [10] that [3+2]-cycloaddition of two-fold excess of azomethine ylides generated *in situ* from isatines and aminoacids to 1,6-bismaleinimidoheptane led to formation of hexamethylene-N,N'-bis-spiroindole-3,3'-pyrrolo[3,4-с]pyrрол-2а',5а'-дигидро-2,2',6'(1H,3'H,5'H)-трионы. These compounds showed a significant antibacterial activity. In continuation of the studies devoted to the search of new antibacterial agents we synthesized the series of ethylene-N,N'-bis(spiroindole-3,3'-pyrроло[3,4-с]pyrроле-2а',5а'-дигидро-2,2',6'(1H,1'H,5'H)-трионе) derivatives [11] (Fig. 2).

N,N'-Di(3-карбоxyпропенoйл)-1,2-этилендиамин was used as a dipolarophile for preparing compounds cited above. This reagent is similar to the antibacterial

drug Ethambutol ((2S,2'S)-2,2'-(Ethane-1,2-diyldiimino)dibutan-1-ol) by its chemical structure [12]. The aim of the current research was to investigate the antibacterial properties of the substances synthesized against standard types of microorganisms (gram-positive and gram-negative).

### Materials and methods

The microbiological studies were performed at the premises of the State Institution "Institute of Microbiology and Immunology named after I. I. Mechnikov of the National Academy of Medical Sciences of Ukraine".

According to the WHO recommendations [13, 14] and recommendations of the Ministry of Health of Ukraine [15, 16] *Staphylococcus aureus* – ATCC 25923, *Escherichia coli* – ATCC 25922, *Pseudomonas aeruginosa* ATCC – 27853, *Bacillus subtilis* ATCC – 6633, *Proteus vulgaris* – ATCC 4636 and *Candida albicans* – ATCC 885/653 were used as test-strains in our study.

*In vitro* evaluation of the antimicrobial activity of the compounds synthesized was performed using the agar diffusion method.

The suspension of microorganisms was prepared on a Densi-La-Meter device (PLIVA-Lachema, Czech Republic; with the wavelength of 540 nm) according to the instruction No. 163-2006 "Standardization of preparation of microbial suspensions" [17-19]. Synchronization of cultures was carried out at the temperature of 4 °C. The microbial load was 10<sup>7</sup> microbial cells per 1 ml of the medium and was determined according to McFarland standard. For experiments the 18-24-hour culture of microorganisms was used. For the research Muller-Hinton agar and Saburo-dextrose agar (for *C. albicans*) were used.

The sample of the compound studied (1 mg) was dissolved in 1 mL of DMSO. 0.3 mL of the solution was taken and introduced into wells on Petri dish with microbial strains. Petri dishes were dried for 30-40 min at room temperature and kept in a thermostat for 18 to 24 h at 37 °C.

The level of the antimicrobial activity was determined as diameters of inhibition growth zones around the well with the compound studied. The results obtained were compared with the strain growth in the control test.

### Results and discussion

The results of the antimicrobial activity of ethylene-N,N'-bis(spiroindole-3,3'-pyrроло[3,4-с]pyrроле-2а',5а'-дигидро-2,2',6'(1H,1'H,5'H)-трионе) derivatives **1-10** are given in Table.





Fig. 1. Alkaloids containing the bis-spirooxindole core

The hexamethylene-*N,N'*-bis(spiroindole-3,3'-pyrrolo[3,4-*c*]pyrrole-2a',5a'-dihydro-2,2',6'(1*H*,1'*H*,5'*H*)-trione) derivatives previously studied showed a high antibacterial activity against *Staphylococcus aureus* and a moderate fungicidal activity against *Candida albicans* [10]. Ethylene-*N,N'*-bis(spiroindole-3,3'-pyrrolo[3,4-*c*]pyrrole-2a',5a'-dihydro-2,2',6'(1*H*,1'*H*,5'*H*)-trione) derivatives **1-10** showed a wider range of the antimicrobial activity. All microorganisms were sensitive to compounds **1-10**. Thus, the growth inhibition zones for all compounds synthesized against *Proteus vulgaris* were on average 1 mm larger compared to the reference drug (Synthomycin). The growth inhibition zones against *Escherichia coli* were on average 2 mm, while against *Pseudomonas aeruginosa* was 5 mm larger for the compounds studied compared to the reference drug. In the case of gram-positive bacteria compounds **1-10** also showed a high activity (the growth inhibition zones against *Staphylococcus aureus*, *Bacillus subtilis* were on average 3 mm larger compared to the reference drug). But the

highest level of activity was found in relation to *Candida albicans* fungi. The growth inhibition zones against fungi were on average 7 mm larger compared to the reference drug (Metronidazole). Thus, in general, the compounds synthesized were even more active than the reference drugs Synthomycin and Metronidazole.




R = H, CH<sub>3</sub>, *i*-Pr, *i*-Bu, Ph, Bn, 4-OH-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-, CH<sub>2</sub>OH;  
R' = H, CH<sub>3</sub>; R=R' = CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>

Fig. 2. The general formula of ethylene-*N,N'*-bis(spiroindole-3,3'-pyrrolo[3,4-*c*]pyrrole-2a',5a'-dihydro-2,2',6'(1*H*,1'*H*,5'*H*)-trione) derivatives

Table

The antimicrobial activity of ethylene-*N,N'*-bis(spiroindole-3,3'-pyrrolo[3,4-*c*]pyrrole-2a',5a'-dihydro-2,2',6'(1*H*,1'*H*,5'*H*)-trione) derivatives **1-10**



Compound	Diameter of the growth inhibition zones*, mm					
	Grampositive bacteria		Gramnegative bacteria			Fungi
	<i>S. aureus</i>	<i>B. subtilis</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>P. vulgaris</i>	<i>C. albicans</i>
<b>1</b> (R = R <sup>1</sup> = H)	16	20	20	22	19	23
<b>2</b> (R = CH <sub>3</sub> ; R <sup>1</sup> = H)	16	20	20	21	19	23
<b>3</b> (R = <i>i</i> -Pr; R <sup>1</sup> = H)	19	21	19	22	18	22
<b>4</b> (R = <i>i</i> -Bu; R <sup>1</sup> = H)	20	20	18	22	17	23
<b>5</b> (R = Ph; R <sup>1</sup> = H)	16	21	17	22	16	22
<b>6</b> (R = <i>i</i> -Pr; R <sup>1</sup> = H)	19	19	20	22	18	23
<b>7</b> (R = Bn; R <sup>1</sup> = H)	16	20	18	22	17	22
<b>8</b> (R = 4-OH-C <sub>6</sub> H <sub>4</sub> -CH <sub>2</sub> -; R <sup>1</sup> = H)	15	20	18	22	17	22
<b>9</b> (R = H; R <sup>1</sup> = CH <sub>3</sub> )	17	20	19	21	18	23
<b>10</b> (R = R <sup>1</sup> = CH <sub>2</sub> -CH <sub>2</sub> -CH <sub>2</sub> )	15	21	19	22	18	22
<b>Control</b>	growth	growth	growth	growth	growth	growth
<b>Synthomycine</b>	14	17	17	17	17	0
<b>Metronidazole</b>	14	16	14	0	0	14

Note: \* – The data presented are the mean values for three experiments relative to each microorganism culture.

## CONCLUSIONS

The antibacterial activity of ethylene-*N,N'*-bis(spiroindole-3,3'-pyrrolo[3,4-*c*]pyrrolo-2a',5a'-dihydro-2,2',6'(1*H*,1'*H*,5'*H*)-trione) derivatives has been studied. The compounds with a significant level of the antimicrobial activity against gramnegative bacteria (*Proteus vulgaris*, *Escherichia coli*, *Pseudomonas aeruginosa*), grampositive bacteria (*Staphylococcus aureus*, *Bacillus subtilis*), as well as against fungi (*Candida*

*albicans*) have been found. According to the data of the microbiological screening the most active compounds appeared to be ethylene-*N,N'*-bis(spiroindole-3,3'-pyrrolo[3,4-*c*]pyrrolo-2a',5a'-dihydro-2,2',6'(1*H*,1'*H*,5'*H*)-trione) **1** and ethylene-*N,N'*-bis(spiroindole-3,3'-pyrrolo[3,4-*c*]pyrrolo-5'-methyl-2a',5a'-dihydro-2,2',6'(1*H*,1'*H*,5'*H*)-trione) **2**.

**Conflict of Interest:** authors have no conflict of interests to declare.

## REFERENCES

1. Информационный бюллетень ВОЗ № 310 «10 ведущих причин смерти в мире», 2014.
2. Ball-Jones, R. B. Strategies for the enantioselective synthesis of spirooxindoles / R. B. Ball-Jones, J. J. Badillo, A. K. Franz // *Org. Biomol. Chem.* – 2012. – Vol. 10, Issue 27. – 5165 p. doi: 10.1039/c2ob25184a
3. Швец, А. А. Синтез бис-β,β'-спиропирролидиноксиндолов, содержащих роданиновый фрагмент / А. А. Швец, С. В. Курбатов // *Химия гетероцикл. соед.* – 2012. – № 5. – С. 859–866.
4. Palyulin, V. Virtual Screening Workflow for Glycogen Synthase Kinase 3β Inhibitors: Convergence of Ligand-based and Structure based Approaches / V. Palyulin, D. I. Osolodkin, N. S. Zefirov // 6-th German Conf. on Chemoinformatics. Abstract Book. – 2010. – 73 p.
5. Зефирова, О. Н. Методологические основы создания лекарственных препаратов / О. Н. Зефирова, Н. С. Зефилов // *Вестн. Моск. ун-та.* – 2000. – № 2. – С. 103–108.
6. Takayama, H. Monoterpenoid Bisindole Alkaloids / H. Takayama, M. Kitajima // *Graduate School of Pharmac. Sci.* – 2016. – P. 259–307.
7. Base-catalyzed one-pot synthesis of dispiro-1,3-dioxolane bisoxindoles from *N*-methylisatin and methyl propiolate / S. Y. Kim, H. J. Roh, D. Y. Seo et al. // *Tetrahedron Lett.* – 2017. – Vol. 58, Issue 10. – P. 914–918. doi: 10.1016/j.tetlet.2017.01.055
8. Bisindole Alkaloids with Neural Anti-inflammatory Activity from *Gelsemium elegans* / Q. Jing, F. Lei, R. Xiao-Dong et al. // *J. Nat. Prod.* – 2013. – Vol. 76, Issue 12. – P. 2203–2209. doi: 10.1021/np4005536
9. Geleganidines A–C, Unusual Monoterpenoid Indole Alkaloids from *Gelsemium elegans* / Z. Wei, H. Xiao-Jun, Z. Sheng-Yuan et al. // *J. Nat. Prod.* – 2015. – Vol. 78, Issue 8. – P. 2036–2044. doi: 10.1021/acs.jnatprod.5b00351

10. Synthesis and antimicrobial activity of Bis-Derivatives of 3a',6a'Dihydro-2'H-Spiro[Indole-3,1'-Pyrrolo[3,4-c]Pyrrrole]-2,4',6'(1H,3'H,5'H)-Trione / R. G. Redkin, E. I. Syumka, L. A. Shemchuk, V. P. Chernykh // *J. of Applied Pharm. Sci.* – 2017. – Vol. 7, Issue 06. – P. 069–078. doi: 10.7324/JAPS.2017.70610
11. Дослідження трикомпонентної взаємодії між ізатином,  $\alpha$ -амінокислотами і N,N'-ди(3-карбоксіпропеноїл)-1,2-етилендіаміном та встановлення будови одержаних сполук / Є. І. Сюзьма, Р. Г. Редькін, Л. А. Шемчук, В. П. Черних // *Журн. орг. та фарм. хімії.* – 2018. – № 1 (61). – P. 34–41. doi: 10.24959/ophcj.18.932
12. *Фармацевтична хімія : підруч.* / ред. П. О. Безуглий. – Вінниця : Нова Книга, 2008. – 560 с.
13. *Методы получения химических реактивов и препаратов.* – М., 1960. – 85 с.
14. Balouiri, M. Methods for in vitro evaluating antimicrobial activity : A review / M. Balouiri, M. Sadiki, S. Ibensouda // *J. Pharm. Analysis.* – 2016. – Vol. 6, Issue 2. – P. 71–79. doi: 10.1016/j.jpha.2015.11.005
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement / J. B. Patel, F. R. Cockerill, P. A. Bradford et al. // *Document M100-S25.* – 2015. – Vol. 35, Issue 3.
16. Вивчення специфічної активності протимікробних лікарських засобів : метод. рек. МОЗ України / Ю. Л. Волянський, І. С. Гриценко, В. П. Ширококов та ін. – К. : ДФЦ МОЗ України, 2004. – 38 с.
17. *Державна фармакопея України / Державне підприємство «Український науковий фармакопейний центр якості лікарських засобів».* – 1-е вид. – X. : Український науковий фармакопейний центр якості лікарських засобів, 2001.
18. Бактеріологічний контроль поживних середовищ : інформаційний лист / МОЗ України № 05. 4. 1 / 1670. – К., 2000. – 4 с.
19. American Society for Microbiology. *Manual of Antimicrobial Susceptibility Testing.* American Society for Microbiology. – Washington, 2005. – 236 p.

## REFERENCES

1. 10 vedushchikh prichin smerti v mire. (2014). *Informatcionnyi biulleten VOZ № 310.*
2. Ball-Jones, N. R., Badillo, J. J., Franz, A. K. (2012). Strategies for the enantioselective synthesis of spirooxindoles. *Organic & Biomolecular Chemistry*, 10 (27), 5165. doi: 10.1039/c2ob25184a
3. Shvetc, A. A., Kurbatov, S. V. (2012). *Khimiia geterotycklicheskikh soedinenii*, 5, 859–866.
4. Palyulin, V. A., Osolodkin, D. I., Zefirov, N. S. (2010). Virtual Screening Workflow for Glycogen Synthase Kinase 3 $\beta$  Inhibitors: Convergence of Ligand-based and Structure based Approaches. *6th German Conference on Chemoinformatics. Abstract Book*, 73.
5. Zefirova, O. N., Zefirov, N. S. (2000). *Vestnik Moskovskogo Universiteta*, 2, 103–108.
6. Takayama, H., Kitajima, M. (2016). Monoterpenoid Bisindole Alkaloids. *Graduate School of Pharmaceutical Sciences*, 259–307.
7. Kim, S. Y., Roh, H. J., Seo, D. Y., Ryu, J. Y., Lee, J., Kim, J. N. (2017). Base-catalyzed one-pot synthesis of dispiro-1,3-dioxolane bisoxindoles from N-methylisatin and methyl propiolate. *Tetrahedron Letters*, 58 (10), 914–918. doi: 10.1016/j.tetlet.2017.01.055
8. Qu, J., Fang, L., Ren, X.-D., Liu, Y., Yu, S.-S., Li, L., Ma, S.-G. (2013). Bisindole Alkaloids with Neural Anti-inflammatory Activity from *Gelsemium elegans*. *Journal of Natural Products*, 76 (12), 2203–2209. doi: 10.1021/np4005536
9. Zhang, W., Huang, X.-J., Zhang, S.-Y., Zhang, D.-M., Jiang, R.-W., Hu, J.-Y., Ye, W.-C. (2015). Geleganidines A–C, Unusual Monoterpenoid Indole Alkaloids from *Gelsemium elegans*. *Journal of Natural Products*, 78 (8), 2036–2044. doi: 10.1021/acs.jnatprod.5b00351
10. Redkin, R. G., Syumka, E. I., Shemchuk, L. A., Chernykh, V. P. (2017). Synthesis and antimicrobial activity of Bis-Derivatives of 3a',6a' Dihydro-2'H-Spiro[Indole-3,1'-Pyrrolo[3,4-c]Pyrrrole]-2,4',6'(1H,3'H,5'H)-Trione. *Journal of Applied Pharmaceutical Science*, 7 (06), 069–078. doi: 10.7324/JAPS.2017.70610
11. Syumka, Y. I., Shemchuk, L. A., Chernykh, V. P., Redkin, R. G. (2018). The study of the three-component interaction between isatin,  $\alpha$ -amino acids and N,N'-di(3-carboxypropenoyl)-1,2-ethylenediamine and determination of the structure of the compounds obtained. *Žurnal Organičnoї Ta Farmaceutičnoї Himiї*, 16 (1(61)), 34–41. doi: 10.24959/ophcj.18.932
12. Bezuglyi, P. O. (2008). *Farmatsevtichna khimiia*. Vinnytsia: Nova knyha, 560.
13. *Metody polucheniia khimicheskikh reaktivov i preparatov.* (1960). Moscow, 85.
14. Balouiri, M., Sadiki, M., Ibensouda, S. K. (2016). Methods for in vitro evaluating antimicrobial activity: A review. *Journal of Pharmaceutical Analysis*, 6 (2), 71–79. doi: 10.1016/j.jpha.2015.11.005
15. Patel, J. B., Cockerill, F. R., Bradford, P. A. et al. (2015). Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. *Document M100-S25*, 35 (3).
16. Volianskyi, Yu. L., Hrytsenko, I. S., Shyrobokov, V. P. et al. (2004). *Iyvchennia spetsyfichnoi aktyvnosti protymikrobykh likarskykh zasobiv*. Kyiv: DFTs MOZ Ukrainy, 38.
17. *Derzhavna farmakopeia Ukrainy, 1 vyd.* (2001). Kharkiv: Ukrainyskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv.
18. Бактеріологічний контроль поживних середовищ. (2000). *Informatsiynyi lyst MOZ Ukrainy № 05. 4. 1 / 1670*. Kyiv, 4.
19. American Society for Microbiology. *Manual of Antimicrobial Susceptibility Testing.* American Society for Microbiology. (2005). Washington, 236.

**Information about authors:**

Syumka Ye. I., teaching assistant of the Organic Chemistry Department, National University of Pharmacy. E-mail: evge17smk@gmail.com  
Osolodchenko T. P., Candidate of Biology (Ph.D.), senior researcher, head of the Laboratory of Biochemistry and Biotechnology, State Institution "Institute of Microbiology and Immunology named after I. I. Mechnikov of the NAMS of Ukraine. E-mail: imi\_lbb@ukr.net  
Chernykh V. P., Doctor of Chemistry (Dr. habil.), Doctor of Pharmacy (Dr. habil.), professor, academician of the National Academy of Sciences of Ukraine, National University of Pharmacy  
Shemchuk L. A., Doctor of Chemistry (Dr. habil.), professor, head of the Organic Chemistry Department, National University of Pharmacy

**Відомості про авторів:**

Сюмка Є. І., асистент кафедри органічної хімії, Національний фармацевтичний університет. E-mail: evge17smk@gmail.com  
Осолодченко Т. П., канд. біол. наук, старший науковий співробітник, завідувач лабораторії біохімії та біотехнології, Державна установа «Інститут мікробіології та імунології імені І. І. Мечникова НАМН України». E-mail: imi\_lbb@ukr.net  
Черних В. П., д-р хім. наук, д-р фарм. наук, професор, академік НАН України, Національний фармацевтичний університет  
Шемчук Л. А., д-р хім. наук, професор, зав. кафедри органічної хімії, Національний фармацевтичний університет

**Сведения об авторах:**

Сюмка Е. И., ассистент кафедры органической химии, Национальный фармацевтический университет. E-mail: evge17smk@gmail.com  
Осолодченко Т. П., канд. биол. наук, старший научный сотрудник, зав. лабораторией биохимии и биотехнологии, Государственное учреждение «Институт микробиологии и иммунологии имени И. И. Мечникова НАМН Украины». E-mail: imi\_lbb@ukr.net  
Черных В. П., д-р хим. наук, д-р фарм. наук, профессор, академик НАН Украины, Национальный фармацевтический университет  
Шемчук Л. А., д-р хим. наук, профессор, зав. кафедрой органической химии, Национальный фармацевтический университет

*Надійшла до редакції 18.11.2017 р.*